drugset / Trial / NCT02716610

Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes

NCT02716610

Phase 1/2 Completed 24 enrolled Dance Biopharm Inc.
RandomizedCrossoverOpen-label

Summary

Pharmacokinetic (PK) and Pharmacodynamic (PD) dose-response investigation of Dance-501 inhaled human insulin

Timeline

Start
2013-10
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject INH Unknown 69 iu Inhaled
Subject INH Unknown 139 iu Inhaled
Subject INH Unknown 208 iu Inhaled
Comparator Insulin Lispro Protein / enzyme biologic 18 iu Subcutaneous